Security
Modular Medical, Inc. Common Stock · MODD
MODDNASDAQCommon stockCurrentCIK 1074871Updated Nov 11, 2026
MODD price & chart
Loading TradingView…
NASDAQ:MODD on TradingView ↗About the company
We are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two part patch pump, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification to the United States Food and Drug Administration (the “FDA”) for our initial product, our MODD1, and, in September 2024, we received FDA clearance to market and sell our MODD1 pump in the United States. In August 2025, we announced the first human use of our MODD1 pump delivering insulin to a h…
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07
ARS filing
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 10,259,000Source | 12,149,000Source | 6,199,000Source | 12,974,000Source | 8,771,000Source | 12,253,000Source | 14,171,000Source | 10,072,000Source | 14,832,000Source | 18,735,000Source | 13,807,000Source | 7,245,248Source |
| Property, Plant and Equipment, NetUSD | 6,327,000Source | 3,958,000Source | 2,634,000Source | 6,459,000Source | 3,641,000Source | 7,090,000Source | 5,212,000Source | 3,619,000Source | 6,866,000Source | 4,453,000Source | 2,975,000Source | 1,721,311Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,937,000Source | 6,986,000Source | 2,047,000Source | 5,316,000Source | — | 3,920,000Source | 7,522,000Source | — | 6,942,000Source | 13,095,000Source | 9,232,000Source | 3,799,324Source |
| Assets, CurrentUSD | 3,466,000Source | 7,331,000Source | 2,342,000Source | 5,947,000Source | 4,176,000Source | 4,845,000Source | 8,292,000Source | 5,407,000Source | 7,542,000Source | 13,517,000Source | 9,697,000Source | 4,046,190Source |
| Prepaid Expense and Other Assets, CurrentUSD | 529,000Source | 345,000Source | 295,000Source | 631,000Source | 283,000Source | 925,000Source | 770,000Source | 355,000Source | 600,000Source | 422,000Source | 465,000Source | 146,866Source |
| Operating Lease, Right-of-Use AssetUSD | 466,000Source | 860,000Source | 1,223,000Source | 568,000Source | 954,000Source | 257,000Source | 667,000Source | 1,046,000Source | 363,000Source | 765,000Source | 1,135,000Source | 1,477,747Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | 61,000Source | — | — | 61,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,378,000Source | 1,887,000Source | 2,354,000Source | 4,205,000Source | 1,855,000Source | 1,489,000Source | 2,328,000Source | 2,056,000Source | 1,873,000Source | 1,658,000Source | 2,272,000Source | 2,169,272Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 78,000Source | 41,000Source | 21,000Source | 61,000Source | 34,000Source | 6,000Source | 55,000Source | 32,000Source | 5,000Source | 54,000Source | 32,000Source | 10,949Source |
| Additional Paid in CapitalUSD | 112,402,000Source | 90,047,000Source | 65,472,000Source | 107,515,000Source | 81,904,000Source | 130,111,000Source | 103,243,000Source | 78,050,000Source | 125,949,000Source | 101,776,000Source | 77,432,000Source | 53,523,734Source |
| Retained Earnings (Accumulated Deficit)USD | -106,605,000Source | -79,826,000Source | -61,648,000Source | -99,245,000Source | -75,022,000Source | -119,481,000Source | -91,455,000Source | -70,066,000Source | -112,995,000Source | -84,753,000Source | -65,929,000Source | -48,458,707Source |
| Stockholders' Equity Attributable to ParentUSD | 5,881,000Source | 10,262,000Source | 3,845,000Source | 8,769,000Source | 6,916,000Source | 10,764,000Source | 11,843,000Source | 8,016,000Source | 12,959,000Source | 17,077,000Source | 11,535,000Source | 5,075,976Source |
| Liabilities and EquityUSD | 10,259,000Source | 12,149,000Source | 6,199,000Source | 12,974,000Source | 8,771,000Source | 12,253,000Source | 14,171,000Source | 10,072,000Source | 14,832,000Source | 18,735,000Source | 13,807,000Source | 7,245,248Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,179,000Source | 1,383,000Source | 1,439,000Source | 4,044,000Source | 1,244,000Source | 1,489,000Source | 2,050,000Source | 1,342,000Source | 1,873,000Source | 1,265,000Source | 1,455,000Source | 979,305Source |
| Operating Lease, Liability, CurrentUSD | 464,000Source | 410,000Source | 362,000Source | 450,000Source | 398,000Source | 278,000Source | 437,000Source | 386,000Source | 393,000Source | 423,000Source | 373,000Source | 355,224Source |
| Accounts Payable, CurrentUSD | 1,008,000Source | 522,000Source | 704,000Source | 2,879,000Source | 501,000Source | 604,000Source | 1,067,000Source | 461,000Source | 992,000Source | 338,000Source | 802,000Source | 285,383Source |
| Operating Lease, Liability, NoncurrentUSD | 40,000Source | 504,000Source | 915,000Source | 161,000Source | 611,000Source | — | 278,000Source | 714,000Source | — | 393,000Source | 817,000Source | 1,189,967Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 707,000Source | 451,000Source | 373,000Source | 715,000Source | 345,000Source | 607,000Source | 546,000Source | 495,000Source | 488,000Source | 504,000Source | 280,000Source | 338,698Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 447,000Source | 724,000Source | 1,778,000Source | 2,381,000Source | 2,701,000Source | 2,724,048Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -4,387,000Source | -4,400,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,972,000Source | -5,372,000Source | -23,753,000Source | -15,720,000Source | -13,952,000Source | -11,011,644Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -688,000Source | -934,000Source | -3,932,000Source | -2,493,000Source | -1,700,000Source | -1,637,751Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 688,000Source | 934,000Source | 3,932,000Source | 2,493,000Source | 1,700,000Source | 1,637,751Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,638,000Source | 733,000Source | 21,532,000Source | 22,076,000Source | 21,085,000Source | 7,372,347Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | -5,277,048Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,937,000Source | 6,986,000Source | 5,316,000Source | 3,893,000Source | 3,920,000Source | 7,522,000Source | 6,942,000Source | 13,095,000Source | 9,232,000Source | 3,799,324Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 30,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,000Source | 2,000Source | 2,000Source | 1,600Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,000Source | 5,000Source | 4,000Source | 9,000Source | — | — | — | — | 37,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | -21,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,839,000Source | 1,001,000Source | 2,236,000Source | 1,294,000Source | 2,167,000Source | 1,670,000Source | 7,587,000Source | 4,351,000Source | 4,649,000Source | 4,816,567Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,000Source | 2,000Source | — | — | 2,000Source | 2,000Source | 2,000Source | 1,600Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,360,000Source | -4,804,000Source | -7,790,000Source | -4,956,000Source | -6,486,000Source | -6,702,000Source | -28,242,000Source | -18,824,000Source | -17,470,000Source | -13,878,936Source |
| Operating ExpensesUSD | — | — | 7,244,000Source | 4,854,000Source | 7,829,000Source | 4,996,000Source | 6,538,000Source | 6,804,000Source | 27,560,000Source | 19,048,000Source | 17,529,000Source | 13,878,311Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 15,673,000Source | 2,114,000Source | 278,000Source | — |
| Nonoperating Income (Expense) | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Payments for Repurchase of Warrants | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -7,244,000Source | -4,854,000Source | -7,829,000Source | -4,996,000Source | -6,538,000Source | -6,804,000Source | -27,560,000Source | -19,048,000Source | -17,529,000Source | -13,878,311Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,360,000Source | -4,804,000Source | -7,788,000Source | -4,954,000Source | — | — | -28,240,000Source | -18,822,000Source | -17,468,000Source | -13,877,336Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,000Source | 2,000Source | — | — | 2,000Source | 2,000Source | 2,000Source | 1,600Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,360,000Source | -4,804,000Source | -7,790,000Source | -4,956,000Source | -6,486,000Source | -6,702,000Source | -28,242,000Source | -18,824,000Source | -17,470,000Source | -13,878,936Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.11Source | -0.13Source | -0.14Source | -0.14Source | -1.19Source | -3.7Source | -12.36Source | -0.51Source | -0.78Source | -1.28Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.11Source | -0.13Source | -0.14Source | -0.14Source | -1.19Source | -3.7Source | -12.36Source | -0.51Source | -0.78Source | -1.28Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 65,930,000Source | 37,807,000Source | 55,576,000Source | 34,338,000Source | 5,452,000Source | 1,810,000Source | 2,285,000Source | 37,007,000Source | 22,377,000Source | 10,880,527Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 65,930,000Source | 37,807,000Source | 55,576,000Source | 34,338,000Source | 5,452,000Source | 1,810,000Source | 2,285,000Source | 37,007,000Source | 22,377,000Source | 10,880,527Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,000Source | 2,000Source | 2,000Source | 1,600Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 501,000Source | 410,000Source | 1,672,000Source | 1,063,000Source | 426,000Source | 152,399Source |
| General and Administrative ExpenseUSD | — | — | 1,839,000Source | 1,001,000Source | 2,236,000Source | 1,294,000Source | 2,167,000Source | 1,670,000Source | 7,587,000Source | 4,351,000Source | 4,649,000Source | 4,816,567Source |
| Operating ExpensesUSD | — | — | 7,244,000Source | 4,854,000Source | 7,829,000Source | 4,996,000Source | 6,538,000Source | 6,804,000Source | 27,560,000Source | 19,048,000Source | 17,529,000Source | 13,878,311Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | 100,000,000Source | — | 75,000Source | — |
| Other IncomeUSD | — | — | 13,000Source | 50,000Source | 41,000Source | 42,000Source | 52,000Source | 102,000Source | 155,000Source | 226,000Source | 61,000Source | 975Source |
| Research and Development ExpenseUSD | — | — | 5,405,000Source | 3,853,000Source | 5,593,000Source | 3,702,000Source | 4,371,000Source | 5,134,000Source | 19,973,000Source | 14,697,000Source | 12,880,000Source | 9,061,744Source |
| Nonoperating Income (Expense) | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-297993
Registration 333-295255
Registration 333-293842
- Gross proceeds
- 11992867.6
- Net proceeds
- 11153366.87
- Deal price
- 0.1762
- Shares
- 68063948
- Offering price
- $0.176200
- Ticker
- MODD
Underwriters: Maxim Group LLC
Filing attachments
ea030948101ex99-1.htm · S-8 · 2026-10-29
Exhibit 99.1 MODULAR MEDICAL, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN (Effective January 23, 2020, August 11, 2021, January 17, 2023, February 13, 2024, February 28, 2025, January 23, 2026 and October 23, 2026) 1. Purposes of the Plan. The purposes of this Equity Incentive Plan are to attract and retain the best available personnel, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. As …
Read attachment ↗ex99-1.htm · SCHEDULE 13G · 2026-08-13
Exhibit 99.1 AGREEMENT OF THE REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and ac…
Read attachment ↗ex99-2.htm · SCHEDULE 13G · 2026-08-13
Exhibit 99.2 The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
Read attachment ↗ea029476201ex4-1.htm · 10-K · 2026-06-29
Exhibit 4.1 MODULAR MEDICAL, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN (Effective January 23, 2020, August 11, 2021, January 17, 2023, February 13, 2024, February 28, 2025 and January 23, 2026) 1. Purposes of the Plan. The purposes of this Equity Incentive Plan are to attract and retain the best available personnel, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. As used herein, the fo…
Read attachment ↗ea028710801ex99-1.htm · 8-K · 2026-04-21
EX-99.1 4 ea028710801ex99-1.htm PRESS RELEASE DATED APRIL 19, 2026 Exhibit 99.1 Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock SAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. (“Modular Medical” or the “Company”) (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the “Offering”) consisting of 750,000 shares of the Company’s common stock at…
Read attachment ↗ea028661101ex99-1.htm · 8-K · 2026-04-16
EX-99.1 2 ea028661101ex99-1.htm PRESS RELEASE BY MODULAR MEDICAL, INC. DATED APRIL 16, 2026 Exhibit 99.1 Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, CA / ACCESSWIRE / April 16, 2026 / Modular Medical, Inc. (“Modular Medical” or the “Company”) (NASDAQ: MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained …
Read attachment ↗